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Introduction
Kaiser-Permanente was started in the late 1930s
when industrialist Henry J. Kaiser was contracted
by the federal government to build the Grand
Coulee dam at a remote site over the Columbia
river. At the time, the workers at the dam site did
not have access to medical services. Mr Kaiser
sought out the help of a young surgeon, Sidney
Garﬁeld, trained at the University of Southern 
California (Los Angeles, CA, USA), who had previ-
ously set up a small prepaid health-care clinic in the
Mojave desert to provide medical care to construc-
tion workers building an aqueduct from the 
Colorado river to Southern California. Together, 
Dr Garﬁeld and Mr Kaiser replicated the model to
provide comprehensive care to the men, women,
and their families.
Kaiser-Permanente Today
Kaiser-Permanente is a group-model, health-
maintenance organization, a partnership between
the not-for-proﬁt Kaiser Foundation Health Plan
and the Permanente Medical Groups in each of the
eight states in which it operates; 8.2 million
members are cared for nationally, two-thirds of
whom reside in California. It is a fully integrated
health-care delivery system with hospitals (36 in
California), pharmacies (250 in California), and an
insurance function. Kaiser Foundation Health Plan
functions under a mutually exclusive contract with
the Permanente Medical Group. Under this contract
the Permanente Medical Group has full responsi-
bility for decision making that involves direct
patient care, whereas Kaiser Health Plan and 
Hospitals operate the insurance and hospital facil-
ity arms. The Permanente Medical Group is divided
into regional medical groups, each of which oper-
ates a regional Pharmacy and Therapeutics (P & T)
Committee as follows: Northern California, South-
ern California, Oregon, Washington state (Group
Health of Puget Sound), Colorado, Hawaii, Ohio,
mid-Atlantic, and Georgia.
Operating revenues for 2000 were approxi-
mately $17 billion, and the program purchased
approximately $1.5 billion of prescription drugs
nationally, accounting for approximately 2% of the
total output from the US pharmaceutical industry.
Kaiser-Permanente aggressively contracts with
the pharmaceutical manufacturers to obtain the
best price based on formulary decisions made by the
Medical Group. Every physician within the Medical
Group participates in the P & T Committee’s
process by discussing the issue with his/her repre-
sentative from the Regional P & T Committee. Any
physician within the group can use a nonformulary
medication, if he/she deems it medically necessary,
without prior authorization.
Pharmacoeconomic modeling studies are not
generally used to determine which drugs are
included on Kaiser-Permanente’s formulary. Expert
opinions of clinical specialists within the medical
group, particularly those who are most likely to use
a speciﬁc medication, are key to decisions regard-
ing whether to add or to delete a medication from
the KP formulary. If the evidence supports equiva-
lence between two different prescription drugs, then
contracting efforts are focused on achieving the best
price by making manufacturers compete for the
business.
David Campen, MD, has been the medical director of drug
information services for Kaiser-Permanente (KP) Pharmacy
Operations in the California division for the past 6 years. He
is also a practicing rheumatologist in Santa Clara, Califor-
nia, and is concerned with the rapid increase of 18% to 20%
per year in expenditures for prescription medications. In the
context of the Sixth Annual Meeting of the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), he presented the model used for formulary devel-
opment and management of appropriate use of pharmaceu-
ticals at Kaiser-Permanente. Dr Campen is concerned,
however, with the continued willingness of purchasers to
include prescription drugs in health-care beneﬁts.
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Outside of Kaiser-Permanente, each health plan
decides which therapeutic agents are included on
their formulary, based on rebates negotiated with
manufacturers. Physicians are required to comply
with the formulary when prescribing to patients
enrolled in the plan. Physicians who contract with
multiple health plans deal with multiple different
formularies and must determine which drug can 
be used for any given patient who walks through
their door. In contrast, 93% of Kaiser-Permanente
members have access to the KP drug beneﬁt [1],
which enables physicians within the Medical Group
to rely on only one formulary, whose development
they are responsible for. Care is further enhanced
by systems that deliver real-time information about
drug use and compliance, allergy information, and
potential drug interactions to the clinic. Physicians
have a greater degree of ﬂexibility within this HMO
structure, because internal formularies are easy and
clear to use and they have more freedom to pre-
scribe the drugs that their patients need. Alterna-
tives also exist for patients unable to be treated with
one of the drugs included on Kaiser-Permanente’s
formulary through a physician-driven, formulary-
exception process that does not require prior 
authorization.
Physicians are not economically credentialed on
utilization decisions that they make, but they are
evaluated on quality of care and patient outcomes.
Here is an example from my practice in which
physician evaluations are based not on the means
but on the outcomes among diabetic patients. Eval-
uation of glycemic control via HbA1c measurement
among a physician’s panel of patients is one
example of such outcome monitoring [2]. Another
example of a physician’s evaluation quality is
his/her use of inhaled beta-agonists versus inhaled
corticosteroids (AI Ratio) [3]. This goal helps drive 
the widely accepted practice of preferential use of
chronic maintenance inhaled corticosteroids for
patients with asthma. Graphic representations of
this information (Fig. 1) are presented to physicians
on a periodic basis. The use of such information has
resulted in improved patient care.
Within Kaiser-Permanente there are many spe-
cialty groups. When new drugs come to market, the
process within Kaiser-Permanente involves submit-
ting the new chemical entity to the Pharmacy Oper-
ations Division and conducting a full detailed
analysis of existing therapies and of the evidence
available on the new drug, which is provided to spe-
cialty chiefs in a monograph form. Their opinion 
is solicited in terms of the distinct advantages that
this new therapy offers, relative price information
for competing pharmaceuticals in the same area,
and the opinions of physicians at large.
The expenditure for health care over a 10-year
interval in this integrated system is illustrated in
Figure 2. The point of concern is the doubling of
expenditures for pharmaceuticals and whether that
shift represents changes based on the true health-
care value of the pharmaceuticals being used.
 
Figure 1 Medical center AI ratio of Internal Medicine (MED) and Urgent Illness (URG) excluding pulmonology, total canister ≥ 25, 1995 to
1998, ages 18 to 50.AI ratio is the ratio of inhaled corticosteroids versus beta agonists used to treat asthmatic patients. Clear, 1995; dark gray,
1996; light gray, 1997; black, 1998.
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Within Kaiser-Permanente, physicians can 
prescribe nonformulary prescription drugs without
prior authorization. Guidelines for the use of non-
formulary drugs are developed under the guidance
of specialists within the medical group. The guide-
lines for the use of cyclooxygenase (COX)-2
inhibitors are an excellent example. Using a risk
stratiﬁcation tool developed collaboratively
between Stanford University and Kaiser-
Permanente [4], patients are scored for their rela-
tive risk of developing a gastrointestinal bleed from
nonsteroidal anti-inﬂammatory drugs (NSAIDs)
based on ﬁve criteria, and the outcomes are plotted
as shown in Figures 3 and 4. The criteria are:
1. Age (the older the patient, the more likely they
are to bleed);
2. Prior bleed (intuitive part of the medical history);
3. Concomitant prednisone use;
4. Diagnosis of rheumatoid arthritis (concomitant
use of NSAIDs or aspirin);
5. Patient’s assessment of his/her own health.
The patient’s SCORE is an accurate predictor of
whether they are at risk for developing a gastroin-
testinal (GI) bleed while using NSAIDs. In addition,
Stanford’s analysis using their large arthritis 
database (ARAMIS) demonstrated good GI safety
information for nebumatome (Relafen, SmithKline
Beecham, Philadelphia, PA, USA) and etodolac
(Lodine, ESI Lederle, Inc., Philadelphia, PA, USA).
This information was presented to the Permanente
rheumatologists who agreed that COX-2 agents
should be reserved for those patients at the highest
risk for GI bleed from NSAIDs. Nebumatome and
etodolac was recommended for those at moderate
risk. Using this recommendation, a program to
educate KP physicians on the appropriate use of
COX-2s was developed. Using both educational
materials and peer assessment tools, KP physicians
and specialists have been able to direct the use of
COX-2 agents to those patients who would most
likely beneﬁt. It should be noted that at present, 
of the prescriptions written for NSAIDs by physi-
cians at KP, only 6% are for COX-2 inhibitors 
compared to a national average of 44% in 2000
[IMS data].
In the case of troglitazone (Rezulin), reports in
the medical literature indicated an increased risk of
 
Figure 2 Expenditure for health care over a 10-year interval in Kaiser-Permanente’s integrated system.
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hepatotoxicity [5]. Chiefs of endocrinology were
asked to review these data. At about that time, a
new glitazone became available for which there was
some safety data deemed to be accurate enough to
warrant conversion of Kaiser-Permanente’s diabetic
patients. Physicians in chief and clinicians sup-
ported the idea, after which a campaign within the
medical group was launched to encourage conver-
sion of members from rezulin to an alternative dia-
betes drug. By the time rezulin was taken off the
market, 90% of Kaiser-Permanente’s patients had
already been converted. The goal was safety, not
cost savings, because the shift was cost-neutral.
Discussion
Conﬂicting evidence in the literature presents a sig-
niﬁcant challenge to decision makers addressing
appropriate pharmaceutical management. Develop-
ing a pharmaceutical beneﬁt design that is nimble
enough to address new developments is difﬁcult.
Emerging controversy over the cardiac safety proﬁle
of COX-2 agents is one example. Shortly after the
release of rofecoxib (Vioxx, Merck & Co., Inc.,
Whitehouse Station, NJ, USA), information sur-
faced regarding an associated risk of myocardial
infarction [6]. In our integrated health-care system,
because every physician has access to complete
comprehensive information about hospitalization,
pharmaceutical use, clinic visits, and laboratory and
radiology results, he/she can easily respond to new
clinical developments and integrate them into
patient-care plans without the hindrance of prior
authorization. For patients seen emergently outside
Kaiser-Permanente’s facilities, the therapeutic deci-
sions are left to the treating physician.
Conclusion
Drug beneﬁt design is used as a tool to manage 
utilization of prescription drugs. Careful analysis of
new therapies by clinical specialists and pharmacists
along with extensive education and information has
been a major tool used within KP. Education of the
Figure 3 The SCORE tool, used to predict the risk for development a GI bleed with ongoing NSAID use.
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medical staff includes the broad distribution of
guidelines as they pertain to drug use as well as
other resource areas, such as laboratory and radi-
ology. Quality guidelines are the chief drivers of 
utilization. Kaiser-Permanente is also investing sub-
stantial resources into the development of an inte-
grated, computerized medical record system to
make all clinical information including laboratory,
x-ray, and pharmaceutical information available at
the time of patient interaction. Decision support
and guidelines based on clinical evidence regarding
the use of pharmaceuticals and other resources are
keys to appropriate management of health-care
resources.
The survival of rich pharmaceutical beneﬁts,
which allow for the appropriate therapy to be
applied without the patient bearing an economic
burden, is threatened. Health-care payers are
increasingly unable and unwilling to bear the full
burden of cost increases experienced over the past
years. Kaiser-Permanente was one of the last HMOs
to convert from a single ﬂat co-pay rate to a tiered
co-pay rate for pharmaceuticals. By the end of
2002, greater than 60% of Kaiser-Permanente’s
members will have a tiered co-pay rate (one amount
for a generic drug and another for a brand-name
drug) as a result of demands from purchasers. This
will introduce major challenges to the partnership
Figure 4 Distribution of risk levels for major GI bleed in nebumatome-naïve patients taking COX-2 inhibitors (March 2001). Risk level 1–2,
lowest; risk level 4, highest.
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that exists between physicians and patients. Ulti-
mately, there exists opportunity for fairly weighing
both therapeutic and economic beneﬁts when select-
ing therapy. — David Campen, MD, Pharmacy
Operations, Kaiser Permanente 1800 Harrison
Street, 13th Fl., Oakland, CA, 94612, USA.
ISPOR gratefully acknowledges John L. Moore
for having transcribed and edited the plenary
session from the 2001 Sixth Annual ISPOR
meeting on which this commentary is based.
Question and Answer Period
Renée Goldberg Arnold, Pharmacon International,
New York, New York
What happens in the case of a patient with rheuma-
toid arthritis who is looking to be on Cox II
inhibitor and is taking ASA?
Campen
In my personal practice among patients at moder-
ate to high risk (of GI bleed?) would prescribe
Relafen. We are using Cox II’s in a small number of
high-risk patients although in view of the data that
has been forthcoming, their use in patients at high
risk of MI is not recommended, and as pointed out,
if receiving ASA therapy, the beneﬁt is negated. The
risk for a GI bleed is similar for all Cox II inhibitors.
The problem is when patients ask why they should-
n’t be prescribed Vioxx, and physicians are faced
with explaining the relative role of these agents over
the long-term.
Renée Goldberg Arnold
Why are internal outcomes resources at KP not
being used for decision-making?
Campen
Internal outcomes as they are developed are given
to the medical group as part of the evidence leading
to a choice of preferred therapy. In my personal
practice among patients at moderate to high risk of
GI bleed I generally use Relafen ﬁrst until there is
better clariﬁcation about the risk of thrombotic
events associated with COX-2s. As a program we
are using COX-2s in about 5% of our NSAID users.
This is preferentially distributed to our high GI
bleed risk patients. Our position, supported by 
Permanente rheumatologists, is that for concurrent
ASA users COX-2 use is not recommended because
of the apparent elimination of beneﬁcial effect.
Renée Goldberg Arnold
Will there be a position paper dealing with where
[G. P. Singh] thinks that the model should be
applied?
Loren Laine, University of Southern California School
of Medicine, Los Angeles, California
David Campen would like to see the evidence in
terms of data and subsets of patients. Can one
predict as ARAMIS claims [which patients will
experience a GI bleed on Cox II’s]? It is not in the
economic interest of the manufacturers to do this
because they have successfully cornered 44% of the
market. In terms of the fourfold increased risk of a
thrombotic event, the manufacturer [Roche] claims
that this is not an issue in view of the antiplatelet
effect of Naprosyn. [However, for this to be true],
naproxen would have to be far superior to aspirin
in terms of its antiplatelet effect.
There is nothing reassuring in terms of the huge
issue facing industry and the FDA regarding label-
ing, which is not out because of the information at
hand, including the quote from the New York Times
indicating that there is an increased risk of throm-
botic events in patients with rheumatoid arthritis.
Unidentiﬁed Participant
What budgetary constraints exist when a budget is
written at the level of the health plan? What deci-
sion rules are applied to determine whether hospi-
tal costs will increase or pharmacy costs decrease?
What method is used to determine how to effec-
tively allocate resources? In the absence of bud-
getary restraints, as long as the therapy is
cost-effective, it should be purchased, but when one
has to prioritize, what decision rules are used?
Campen
There is no clear answer. Decisions of this nature
are made by the medical group rather than by the
health plan. Physicians have their own medical
group that employs them and contracts with the
health plan to provide services. The medical group
has the responsibility for clinical decisions with
respect to purchasing and clinical care. The appli-
cation of a [decision tree] algorithm is not possible.
No health-care plan wants to encourage decreased
pharmacy expenditure at the expense of increased
hospital costs. Scarce resources should be allocated
effectively and clinically sound, cost-effective
therapy should be the aim whether outpatient drugs
or inpatient hospital care.
389Formulary Development in HMOs
Presented at the Sixth Annual ISPOR Meeting, May 23,
2001, Arlington Virginia
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